about
Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist.Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status.Diabetes and Hypertension: A Position Statement by the American Diabetes Association.Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not.Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes.Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events.Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial.Big Topics for DIabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information TechnologyLong-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney diseaseDiabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 DiabetesHyperkalaemia in diabetes: a silent risk predicting poor outcomesMicrovascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL TrialComparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic HypertensionKidney injury is not prevented by hydration aloneNon-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney diseasePrediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCELRenal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
P50
Q47269985-49744759-93DD-4FF8-B51D-046135062A80Q48131950-96836EB8-9505-49D3-A6F3-F8E04A32892FQ48199922-5F5194B9-D80E-402C-9FF0-30A894C863B8Q49791016-5EFEA60F-2610-49C0-8BB4-6F436CCE4964Q50102194-AAF05453-8684-4F4C-A184-042F483CA18EQ51245440-479F9906-48C0-44EC-B6DE-EABBFED6730FQ51731767-E1F38A48-BF9A-401A-9272-5D4126EE6B0AQ56348800-0E08CB69-404A-4484-991D-B06817321964Q87958963-B3C451AA-65D0-4375-955A-E63758DE957BQ88112324-74058A6F-94B8-452B-AD59-8433EB87F3C2Q88780730-86D3A270-0003-43ED-98DF-8C9ABE352EF1Q91403899-09F8CE3F-3B9C-4EF8-834B-99D19A1C3F97Q91454394-D8269E1D-ED4F-4477-A5BB-DB082802AA98Q91536209-2971342D-0566-4AB7-8142-12FE21A7FEC5Q91720431-A5797D7D-0760-4626-9EA1-43A5A88F49F4Q92486873-F3FADE90-B1EC-4069-AC37-EF2D4DB76FE4Q94473468-C3DD8514-C92C-4ECC-A7E0-F7A0BD2C9CFB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
George Bakris
@ast
George Bakris
@en
George Bakris
@es
George Bakris
@nl
type
label
George Bakris
@ast
George Bakris
@en
George Bakris
@es
George Bakris
@nl
prefLabel
George Bakris
@ast
George Bakris
@en
George Bakris
@es
George Bakris
@nl
P106
P21
P31
P496
0000-0003-1183-1267